JP2018530315A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018530315A5 JP2018530315A5 JP2018510813A JP2018510813A JP2018530315A5 JP 2018530315 A5 JP2018530315 A5 JP 2018530315A5 JP 2018510813 A JP2018510813 A JP 2018510813A JP 2018510813 A JP2018510813 A JP 2018510813A JP 2018530315 A5 JP2018530315 A5 JP 2018530315A5
- Authority
- JP
- Japan
- Prior art keywords
- domain
- fusion protein
- btx
- seq
- toxin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108020001507 fusion proteins Proteins 0.000 claims 30
- 102000037865 fusion proteins Human genes 0.000 claims 30
- 108030001720 Bontoxilysin Proteins 0.000 claims 24
- 231100001103 botulinum neurotoxin Toxicity 0.000 claims 23
- 101710194807 Protective antigen Proteins 0.000 claims 22
- 108090000765 processed proteins & peptides Proteins 0.000 claims 19
- 230000005945 translocation Effects 0.000 claims 18
- 239000003053 toxin Substances 0.000 claims 17
- 231100000765 toxin Toxicity 0.000 claims 17
- 108700012359 toxins Proteins 0.000 claims 17
- 108030001722 Tentoxilysin Proteins 0.000 claims 13
- 108020003175 receptors Proteins 0.000 claims 13
- 102000005962 receptors Human genes 0.000 claims 13
- 210000000929 nociceptor Anatomy 0.000 claims 10
- 150000001413 amino acids Chemical class 0.000 claims 8
- 108010055044 Tetanus Toxin Proteins 0.000 claims 7
- 210000004899 c-terminal region Anatomy 0.000 claims 7
- 241000193738 Bacillus anthracis Species 0.000 claims 6
- 241001112695 Clostridiales Species 0.000 claims 6
- 102000004190 Enzymes Human genes 0.000 claims 5
- 108090000790 Enzymes Proteins 0.000 claims 5
- 125000003275 alpha amino acid group Chemical group 0.000 claims 5
- 102000004961 Furin Human genes 0.000 claims 4
- 108090001126 Furin Proteins 0.000 claims 4
- 108010076504 Protein Sorting Signals Proteins 0.000 claims 4
- 230000003197 catalytic effect Effects 0.000 claims 4
- 102000039446 nucleic acids Human genes 0.000 claims 4
- 108020004707 nucleic acids Proteins 0.000 claims 4
- 150000007523 nucleic acids Chemical class 0.000 claims 4
- 108091005804 Peptidases Proteins 0.000 claims 3
- 239000004365 Protease Substances 0.000 claims 3
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims 3
- 238000003776 cleavage reaction Methods 0.000 claims 3
- 210000001163 endosome Anatomy 0.000 claims 3
- 108091008700 nociceptors Proteins 0.000 claims 3
- 102000004196 processed proteins & peptides Human genes 0.000 claims 3
- 230000007017 scission Effects 0.000 claims 3
- 210000002966 serum Anatomy 0.000 claims 3
- 239000013598 vector Substances 0.000 claims 3
- 102100031325 Anthrax toxin receptor 2 Human genes 0.000 claims 2
- 101000796085 Homo sapiens Anthrax toxin receptor 2 Proteins 0.000 claims 2
- 102000000583 SNARE Proteins Human genes 0.000 claims 2
- 108010041948 SNARE Proteins Proteins 0.000 claims 2
- 210000004027 cell Anatomy 0.000 claims 2
- 210000000172 cytosol Anatomy 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 239000012528 membrane Substances 0.000 claims 2
- 230000008685 targeting Effects 0.000 claims 2
- XUNKPNYCNUKOAU-VXJRNSOOSA-N (2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-amino-5-(diaminomethylideneamino)pentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]a Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O XUNKPNYCNUKOAU-VXJRNSOOSA-N 0.000 claims 1
- 101500000960 Bacillus anthracis Protective antigen PA-63 Proteins 0.000 claims 1
- 101100406366 Caenorhabditis elegans pad-2 gene Proteins 0.000 claims 1
- 150000008574 D-amino acids Chemical class 0.000 claims 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 claims 1
- 108010093488 His-His-His-His-His-His Proteins 0.000 claims 1
- 102000004310 Ion Channels Human genes 0.000 claims 1
- 125000000539 amino acid group Chemical group 0.000 claims 1
- 229940053031 botulinum toxin Drugs 0.000 claims 1
- 239000003153 chemical reaction reagent Substances 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 238000012217 deletion Methods 0.000 claims 1
- 230000037430 deletion Effects 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000012202 endocytosis Effects 0.000 claims 1
- 230000002255 enzymatic effect Effects 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 230000003834 intracellular effect Effects 0.000 claims 1
- 210000002569 neuron Anatomy 0.000 claims 1
- 230000003040 nociceptive effect Effects 0.000 claims 1
- 231100000065 noncytotoxic Toxicity 0.000 claims 1
- 230000002020 noncytotoxic effect Effects 0.000 claims 1
- 239000002245 particle Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 239000013612 plasmid Substances 0.000 claims 1
- 229920001184 polypeptide Polymers 0.000 claims 1
- 239000011148 porous material Substances 0.000 claims 1
- 229940118376 tetanus toxin Drugs 0.000 claims 1
- 230000017105 transposition Effects 0.000 claims 1
- 241001515965 unidentified phage Species 0.000 claims 1
- 239000013603 viral vector Substances 0.000 claims 1
- 230000003612 virological effect Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562210610P | 2015-08-27 | 2015-08-27 | |
| US62/210,610 | 2015-08-27 | ||
| PCT/US2016/049099 WO2017035507A1 (en) | 2015-08-27 | 2016-08-26 | Compositions and methods for treatment of pain |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018530315A JP2018530315A (ja) | 2018-10-18 |
| JP2018530315A5 true JP2018530315A5 (enExample) | 2019-10-03 |
Family
ID=58101095
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018510813A Pending JP2018530315A (ja) | 2015-08-27 | 2016-08-26 | 疼痛の治療を目的とする組成物及び方法 |
| JP2018511085A Pending JP2018525021A (ja) | 2015-08-27 | 2016-08-26 | 疼痛の治療を目的とする組成物及び方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018511085A Pending JP2018525021A (ja) | 2015-08-27 | 2016-08-26 | 疼痛の治療を目的とする組成物及び方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (4) | US11753633B2 (enExample) |
| EP (2) | EP3341392A4 (enExample) |
| JP (2) | JP2018530315A (enExample) |
| KR (2) | KR20180050679A (enExample) |
| CN (2) | CN108350039A (enExample) |
| AU (2) | AU2016312685A1 (enExample) |
| BR (2) | BR112018003782A2 (enExample) |
| CA (2) | CA2994729A1 (enExample) |
| EA (1) | EA201890587A1 (enExample) |
| MX (1) | MX2018002183A (enExample) |
| WO (2) | WO2017035507A1 (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20220354962A1 (en) * | 2015-05-12 | 2022-11-10 | The Trustees Of The University Of Pennsylvania | Rapid production of bispecific antibodies from off-the-shelf iggs with high yield and purity |
| TW201718627A (zh) * | 2015-06-11 | 2017-06-01 | 梅茲製藥有限兩合公司 | 重組梭菌神經毒素及其使用與形成方法、包括其之醫藥組合物及對應其之前驅物、編碼前驅物之核酸序列及其獲得方法與前驅物之形成方法、載體與包括核酸序列之重組宿主細胞 |
| US11753633B2 (en) | 2015-08-27 | 2023-09-12 | President And Fellows Of Harvard College | Compositions and methods for treatment of pain |
| GB201607901D0 (en) * | 2016-05-05 | 2016-06-22 | Ipsen Biopharm Ltd | Chimeric neurotoxins |
| UA125965C2 (uk) * | 2016-07-08 | 2022-07-20 | Чілдренс Медікал Сентр Корпорейшн | Новий ботулінічний нейротоксин та його похідні |
| EP3687566A2 (en) * | 2017-09-29 | 2020-08-05 | Children's Medical Center Corporation | A neurotoxin-like toxin and uses thereof |
| CA3083083A1 (en) | 2018-01-29 | 2019-08-01 | Ipsen Biopharm Limited | Non-neuronal snare-cleaving botulinum neurotoxins |
| WO2019158745A1 (de) * | 2018-02-16 | 2019-08-22 | Bontana Therapies Gmbh | Nukleinsäure-basiertes botulinum neurotoxin zur therapeutischen anwendung |
| JP2021525514A (ja) * | 2018-05-30 | 2021-09-27 | ザ ガバニング カウンシル オブ ザ ユニバーシティ オブ トロントＴｈｅ Ｇｏｖｅｒｎｉｎｇ Ｃｏｕｎｃｉｌ Ｏｆ Ｔｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｔｏｒｏｎｔｏ | 受容体−リガンド相互作用に関連付けられるタンパク質を同定するための方法及びキット |
| EP3825333A4 (en) * | 2018-07-06 | 2022-04-06 | Abmax Biopharmaceuticals | LOW FUNCTIONALITY ADCC/CDC MONOCLONAL ANTIBODY, METHOD FOR PREPARATION AND USE |
| CN112638937B (zh) * | 2018-07-31 | 2025-06-17 | 斯诺雷托克斯私人有限公司 | 聚乙二醇化的破伤风神经毒素和张力减退的治疗 |
| WO2020116686A1 (ko) * | 2018-12-06 | 2020-06-11 | 고려대학교 산학협력단 | 인간 항-antxr 키메라 항원 수용체 및 이의 용도 |
| WO2021150581A2 (en) * | 2020-01-21 | 2021-07-29 | Trustees Of Dartmouth College | Immunologically optimized botulinum toxin light chain variants |
| EP4100038A4 (en) | 2020-02-03 | 2024-02-28 | Premas Biotech Private Limited | RECOMBINANT EXPRESSION PLATFORM, CONSTRUCTS AND METHODS FOR EXPRESSING HARD-TO-EXPRESS PROTEINS (DTE-PS) |
| US20230165812A1 (en) * | 2020-02-27 | 2023-06-01 | President And Fellows Of Harvard College | Nociceptor neurons control cancer immunosurveillance |
| GB202104294D0 (en) * | 2021-03-26 | 2021-05-12 | Ipsen Biopharm Ltd | Clostridial neurotoxins comprising an exogenous activation loop |
| KR102728382B1 (ko) * | 2022-10-12 | 2024-11-14 | 주식회사 알케미어 | 보툴리눔 독소의 경쇄 변이체 |
Family Cites Families (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3536809A (en) | 1969-02-17 | 1970-10-27 | Alza Corp | Medication method |
| US3598123A (en) | 1969-04-01 | 1971-08-10 | Alza Corp | Bandage for administering drugs |
| US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
| US3916899A (en) | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
| US4008719A (en) | 1976-02-02 | 1977-02-22 | Alza Corporation | Osmotic system having laminar arrangement for programming delivery of active agent |
| US4737462A (en) | 1982-10-19 | 1988-04-12 | Cetus Corporation | Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of interferon-β |
| US4518584A (en) | 1983-04-15 | 1985-05-21 | Cetus Corporation | Human recombinant interleukin-2 muteins |
| IE58110B1 (en) | 1984-10-30 | 1993-07-14 | Elan Corp Plc | Controlled release powder and process for its preparation |
| US5073543A (en) | 1988-07-21 | 1991-12-17 | G. D. Searle & Co. | Controlled release formulations of trophic factors in ganglioside-lipsome vehicle |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| IT1229203B (it) | 1989-03-22 | 1991-07-25 | Bioresearch Spa | Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative. |
| US5120548A (en) | 1989-11-07 | 1992-06-09 | Merck & Co., Inc. | Swelling modulated polymeric drug delivery device |
| US5733566A (en) | 1990-05-15 | 1998-03-31 | Alkermes Controlled Therapeutics Inc. Ii | Controlled release of antiparasitic agents in animals |
| IL99552A0 (en) | 1990-09-28 | 1992-08-18 | Ixsys Inc | Compositions containing procaryotic cells,a kit for the preparation of vectors useful for the coexpression of two or more dna sequences and methods for the use thereof |
| US5580578A (en) | 1992-01-27 | 1996-12-03 | Euro-Celtique, S.A. | Controlled release formulations coated with aqueous dispersions of acrylic polymers |
| US5591767A (en) | 1993-01-25 | 1997-01-07 | Pharmetrix Corporation | Liquid reservoir transdermal patch for the administration of ketorolac |
| IT1270594B (it) | 1994-07-07 | 1997-05-07 | Recordati Chem Pharm | Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida |
| GB9508204D0 (en) * | 1995-04-21 | 1995-06-07 | Speywood Lab Ltd | A novel agent able to modify peripheral afferent function |
| WO1997023236A1 (en) | 1995-12-13 | 1997-07-03 | President And Fellows Of Harvard College | Use of toxin peptides and/or affinity handles for the delivering compounds into cells |
| US5723125A (en) | 1995-12-28 | 1998-03-03 | Tanox Biosystems, Inc. | Hybrid with interferon-alpha and an immunoglobulin Fc linked through a non-immunogenic peptide |
| GB9526733D0 (en) | 1995-12-30 | 1996-02-28 | Delta Biotechnology Ltd | Fusion proteins |
| WO2001021656A2 (en) * | 1999-09-24 | 2001-03-29 | The Government Of The United State Of America, As Represented By The Secretary, Department Of Health And Human Services | Mutated anthrax toxin protective antigen proteins that specifically target cells containing high amounts of cell-surface metalloproteinases or plasminogen activator receptors |
| US6365185B1 (en) | 1998-03-26 | 2002-04-02 | University Of Cincinnati | Self-destructing, controlled release peroral drug delivery system |
| AUPP627498A0 (en) | 1998-10-02 | 1998-10-22 | University Of Queensland, The | Novel peptides - i |
| US6767896B1 (en) | 1999-01-29 | 2004-07-27 | Cognetix, Inc. | Conotoxin peptides |
| DE60032367T3 (de) * | 1999-08-25 | 2011-03-10 | Allergan, Inc., Irvine | Aktivierbare rekombinante neurotoxine |
| AU2740401A (en) | 1999-12-30 | 2001-07-16 | Cognetix, Inc. | O-superfamily conotoxin peptides |
| CA2486118A1 (en) * | 2002-06-07 | 2003-12-18 | Large Scale Biology Corporation | Flexible vaccine assembly and vaccine delivery platform |
| DE102004043009A1 (de) | 2004-09-06 | 2006-03-23 | Toxogen Gmbh | Transportprotein zum Einbringen chemischer Verbindungen in Nervenzellen |
| EP1858546A4 (en) | 2005-03-04 | 2009-03-04 | Biorexis Pharmaceutical Corp | MODIFIED TRANSFERRINFUSION PROTEINS |
| AU2006339490B2 (en) | 2005-09-19 | 2011-12-08 | Allergan, Inc. | Clostridial toxin activatable clostridial toxins |
| KR101491860B1 (ko) | 2005-11-08 | 2015-02-09 | 애더리스 래버러토리즈 | Ｍｕ-코노톡신 펩티드 및 국소 마취제로서 그의 용도 |
| CA2601537A1 (en) | 2006-03-14 | 2007-09-20 | Allergan, Inc. | Modified clostridial toxins with altered targeting capabilities for clostridial toxin target cells |
| GB0610867D0 (en) | 2006-06-01 | 2006-07-12 | Syntaxin Ltd | Treatment of pain |
| CA2658260A1 (en) | 2006-07-11 | 2008-01-17 | Allergan, Inc. | Modified clostridial toxins with enhanced translocation capabilities and altered targeting activity for clostridial toxin target cells |
| CA2657521A1 (en) | 2006-07-11 | 2008-01-17 | Allergan, Inc. | Modified clostridial toxins with enhanced translocation capabilities and altered targeting activity for non-clostridial toxin target cells |
| US9284358B2 (en) | 2006-07-18 | 2016-03-15 | University Of Utah Research Foundation | Conotoxin peptides |
| AU2012205772B2 (en) | 2011-01-10 | 2015-10-08 | President And Fellows Of Harvard College | Method for delivering agents into cells using bacterial toxins |
| GB201108108D0 (en) | 2011-05-16 | 2011-06-29 | Syntaxin Ltd | Therapeutic fusion proteins |
| JP2015509501A (ja) * | 2012-02-23 | 2015-03-30 | プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ | 剤を細胞へ送達するための改変型微生物毒素受容体 |
| JP2015519344A (ja) | 2012-05-21 | 2015-07-09 | マサチューセッツ インスティテュート オブ テクノロジー | 炭疽菌防御抗原ポアを通しての非天然化学実体のトランスロケーション |
| US20140056870A1 (en) * | 2012-08-27 | 2014-02-27 | Allergan, Inc. | Fusion proteins |
| WO2014088928A1 (en) | 2012-12-03 | 2014-06-12 | President And Fellows Of Harvard College | Methods for making targeted protein toxins by sortase-mediated protein ligation |
| GB201407525D0 (en) | 2014-04-29 | 2014-06-11 | Syntaxin Ltd | Manufacture of recombinant clostridium botulinum neurotoxins |
| US11753633B2 (en) | 2015-08-27 | 2023-09-12 | President And Fellows Of Harvard College | Compositions and methods for treatment of pain |
-
2016
- 2016-08-26 US US15/755,544 patent/US11753633B2/en active Active
- 2016-08-26 CA CA2994729A patent/CA2994729A1/en not_active Abandoned
- 2016-08-26 WO PCT/US2016/049099 patent/WO2017035507A1/en not_active Ceased
- 2016-08-26 KR KR1020187008537A patent/KR20180050679A/ko not_active Withdrawn
- 2016-08-26 BR BR112018003782A patent/BR112018003782A2/pt not_active Application Discontinuation
- 2016-08-26 JP JP2018510813A patent/JP2018530315A/ja active Pending
- 2016-08-26 MX MX2018002183A patent/MX2018002183A/es unknown
- 2016-08-26 CN CN201680062362.0A patent/CN108350039A/zh active Pending
- 2016-08-26 AU AU2016312685A patent/AU2016312685A1/en not_active Abandoned
- 2016-08-26 EP EP16840235.2A patent/EP3341392A4/en active Pending
- 2016-08-26 EA EA201890587A patent/EA201890587A1/ru unknown
- 2016-08-26 KR KR1020187008538A patent/KR20180070563A/ko not_active Withdrawn
- 2016-08-26 WO PCT/US2016/049106 patent/WO2017035508A1/en not_active Ceased
- 2016-08-26 EP EP16840234.5A patent/EP3341391A4/en active Pending
- 2016-08-26 CN CN201680062855.4A patent/CN108602861A/zh active Pending
- 2016-08-26 BR BR112018003794A patent/BR112018003794A2/pt not_active Application Discontinuation
- 2016-08-26 AU AU2016310521A patent/AU2016310521A1/en not_active Abandoned
- 2016-08-26 US US15/755,543 patent/US10704035B2/en active Active
- 2016-08-26 JP JP2018511085A patent/JP2018525021A/ja active Pending
- 2016-08-26 CA CA2994560A patent/CA2994560A1/en not_active Abandoned
-
2020
- 2020-05-27 US US16/884,893 patent/US11104892B2/en active Active
-
2021
- 2021-08-13 US US17/402,323 patent/US20220033795A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018525021A5 (enExample) | ||
| KR102567311B1 (ko) | 보툴리눔 신경독소의 정제 및 활성화 방법 | |
| Futaki et al. | Arginine carrier peptide bearing Ni (II) chelator to promote cellular uptake of histidine-tagged proteins | |
| JP2005120106A5 (enExample) | ||
| KR102040982B1 (ko) | 고용해성 녹색형광 단백질과 보툴리늄 독소 단백질의 융합단백질 구성을 통한 재조합 보툴리늄 독소 단백질의 대량생산 기술 | |
| US6379903B1 (en) | Purification of recombinant proteins fused to multiple epitopes | |
| IL294059A (en) | Mutant rsv f protein and its use | |
| CA2636075A1 (en) | Chimaeric fusion protein with superior chaperone and folding activities | |
| US11118170B2 (en) | Engineered clostridium botulinum toxin adapted to deliver molecules into selected cells | |
| CA2344993A1 (en) | Method for the production of (poly)peptides by using truncated variants of the sv40 large t antigen with an intact n terminus | |
| KR101667023B1 (ko) | 무세포 단백질 합성 방법을 이용하여 생산된 항체의 세포질 내로의 유입을 간편하게 분석하는 방법 | |
| Iwamoto et al. | Synthetic studies on the extracellular domain of the T cell immunoreceptor with immunoglobulin and immunoreceptor tyrosine-based inhibitory motif domain (TIGIT) using Trt-K10 solubilizing tags | |
| JP5757639B2 (ja) | セルピンフィンガー融合ポリペプチド | |
| Murby et al. | Differential degradation of a recombinant albumin‐binding receptor in Escherichia coli | |
| Gruschke et al. | Peptides from the SARS-associated coronavirus as tags for protein expression and purification | |
| WO2005062871A3 (en) | Tat linear epitope peptides and conjugates thereof for use in therapeutic compositions and assays | |
| HK40007330A (en) | Method for purification and activation of botulinum neurotoxin | |
| NZ733789B2 (en) | Binding-triggered transcriptional switches and methods of use thereof | |
| HK40006631B (en) | Method for purification and activation of botulinum neurotoxin | |
| WO1999002706A1 (en) | Glycosylation peptides |